Phase II and III studies with carboplatin in small cell lung cancer.

@article{Gatzemeier1992PhaseIA,
  title={Phase II and III studies with carboplatin in small cell lung cancer.},
  author={Ulrich Gatzemeier and Dieter Kurt Hossfeld and R Neuhauss and Martin Reck and Wolf Achterrath and Luigi Lenaz},
  journal={Seminars in oncology},
  year={1992},
  volume={19 1 Suppl 2},
  pages={28-36}
}
Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The median survival time with this combination was 14 months in patients with LD and 9.5 months in those with extensive disease (ED). The 30-month survival rates are 30% in LD and 10… CONTINUE READING